The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma
EBV特异性T细胞在EBV驱动的鼻咽癌检查点阻断免疫治疗中的作用
基本信息
- 批准号:10681300
- 负责人:
- 金额:$ 60.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:Adoptive ImmunotherapyAftercareAmerican Association of Cancer ResearchBiopsyBiopsy SpecimenBloodBlood specimenCD8-Positive T-LymphocytesCancer CenterCellsCharacteristicsClinicalClinical TrialsClone CellsCytometryDataDiagnosisEnrollmentEpstein-Barr Virus-Related Malignant NeoplasmFar EastFreezingFutureGene ExpressionGene Expression ProfileGene Expression ProfilingGenetic TranscriptionGoalsHLA-DR AntigensHead and Neck CancerHuman Herpesvirus 4ImmuneImmune EvasionImmune responseImmunohistochemistryImmunologic SurveillanceImmunologicsImmunotherapeutic agentImmunotherapyInfiltrationLymphocyteMalignant NeoplasmsMediatingMemoryMetastatic/RecurrentMethodsNasopharynx CarcinomaNewly DiagnosedOutcomeParticipantPatient SelectionPatientsPatternPeptide/MHC ComplexPeripheralPeripheral Blood Mononuclear CellPersonsPhase II Clinical TrialsPhenotypePopulationPrevalencePublishingRoleSamplingSingaporeSortingSoutheastern AsiaStainsSurvival RateT cell receptor repertoire sequencingT cell responseT-Cell ActivationT-Cell ReceptorT-LymphocyteT-cell receptor repertoireTestingTimeTissuesTumor TissueTumor-Infiltrating LymphocytesValidationVirus Diseasesanti-CTLA4anti-PD-1anti-PD1 therapycancer diagnosiscellular imagingclinically relevantcohortexhaustgenetic signatureimmune checkpoint blockadeimmunopathologyimmunotherapy trialsimprovedinsightipilimumabmultiple omicsnovelperipheral bloodphase II trialprogrammed cell death ligand 1protein expressionresponsesingle cell sequencingtumortumor microenvironmentviral DNA
项目摘要
Project Summary/Abstract
Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-driven malignancy that is endemic to East and
Southeast Asia. The overall 5-year survival rate for endemic NPC is only 51%, which represents an unmet clinical
need. While NPC tumors are known to be infected with EBV and express PD-L1, little is known about the role of
EBV-specific T cells in the control of NPC and anti-PD-1 therapy has shown a low rate of efficacy (ORR ~20%).
The goal of this study is to better understand the role of EBV-specific T cell responses in NPC immunopathology
and immunotherapeutic response. We will test the specific hypotheses that: 1. EBV-specific T cells contribute to
tumor control elicited by combination anti-PD-1 and anti-CTLA-4 checkpoint blockade immunotherapy, and 2.
that the phenotypic and clonal characteristics/dynamics of peripheral EBV-specific T cells can be useful as
indicators of clinical outcomes for NPC patients. To test these hypotheses, we will leverage our access to two
Singaporean NPC patient cohorts: Cohort 1. A 51-patient cohort of new-diagnosis NPC for which viably frozen
PBMCs and archival FFPE tissues are available and Cohort 2. A 50-patient cohort participating in a phase II
trial (NCT03097939 - National Cancer Centre Singapore) testing the combination of Ipilumimab and
Nivolumimab (Ipi.+Nivo.) immunotherapy with longitudinally collected PBMCs and tissue biopsies. Recently
published preliminary analysis (AACR 2020) from this clinical trial shows that combined Ipi.+Nivo. therapy is safe
and achieved durable responses in recurrent and metastatic NPC patients and identified a negative association
between circulating EBV-DNA levels and response. In addition, preliminary analysis of new-diagnosis NPC
patient peripheral blood samples from Cohort 1 show associations between certain phenotypic profiles of CD8+
T cells and clinical parameters such as EBV-DNA levels. Therefore, in Aim 1. we will investigate the clinical
relevance of these preliminarily identified NPC-associated CD8+ T cell phenotypes. In addition to in-depth single
cell transcriptional, functional TCR sequence profiling of these cells, cellular imaging, transcriptional profiling and
bulk TCR sequencing of patient-matched tumor will allow discovery of novel associations between peripheral T
cells and the tumor microenvironment. In Aim 2., we will characterize EBV-specific T cell responses in the NPC
periphery and tumor microenvironment during combination Ipi.+Nivo. immunotherapy treatment to identify novel
associations between the phenotypic profiles of EBV-specific T cells and immunotherapeutic response. In Aim
3., we will investigate T cell clonal dynamics associated with treatment induced changes to the NPC-specific
immune response by comparing the TCR clonal diversity in peripheral blood and tumor biopsy samples from
different stages of treatment. Overall, characterization of EBV-specific T cells phenotypes in the NPC periphery
and the tumor using multiple cutting-edge approaches will not only improve our understanding of the NPC
immune landscape, but also potentially identify clinically relevant EBV-specific T cell phenotypes that could be
tested in future NPC immunotherapy trials.
项目概要/摘要
鼻咽癌 (NPC) 是一种由 Epstein-Barr 病毒 (EBV) 驱动的恶性肿瘤,在东部和东部地区流行。
东南亚。地方性鼻咽癌的总体5年生存率仅为51%,这是一个未满足的临床目标
需要。虽然已知鼻咽癌肿瘤感染 EBV 并表达 PD-L1,但人们对 EBV 的作用知之甚少。
EBV特异性T细胞在鼻咽癌的控制和抗PD-1治疗中显示出较低的疗效(ORR~20%)。
本研究的目的是更好地了解 EBV 特异性 T 细胞反应在鼻咽癌免疫病理学中的作用
和免疫治疗反应。我们将测试以下具体假设: 1. EBV 特异性 T 细胞有助于
通过联合抗 PD-1 和抗 CTLA-4 检查点阻断免疫疗法引起肿瘤控制,以及 2.
外周 EBV 特异性 T 细胞的表型和克隆特征/动力学可用作
鼻咽癌患者的临床结果指标。为了检验这些假设,我们将利用我们对两个
新加坡鼻咽癌患者队列:队列 1。包含 51 名新诊断鼻咽癌患者的队列,对其进行活体冷冻
PBMC 和存档 FFPE 组织可用,队列 2。参与 II 期的 50 名患者队列
试验(NCT03097939 - 新加坡国家癌症中心)测试 Ipilumimab 和
Nivolumimab (Ipi.+Nivo.) 使用纵向收集的 PBMC 和组织活检进行免疫治疗。最近
该临床试验已发表的初步分析 (AACR 2020) 显示,Ipi.+Nivo 相结合。治疗是安全的
在复发性和转移性鼻咽癌患者中取得了持久的反应,并确定了负相关
循环 EBV-DNA 水平与反应之间的关系。另外,对新诊断鼻咽癌的初步分析
来自队列 1 的患者外周血样本显示 CD8+ 的某些表型特征之间存在关联
T 细胞和临床参数,例如 EBV-DNA 水平。因此,在目标 1 中,我们将研究临床
这些初步确定的 NPC 相关 CD8+ T 细胞表型的相关性。除了深入单
细胞转录、这些细胞的功能性 TCR 序列分析、细胞成像、转录分析和
对患者匹配肿瘤进行批量 TCR 测序将有助于发现外周 T 细胞之间的新关联
细胞和肿瘤微环境。在目标 2. 中,我们将描述 NPC 中 EBV 特异性 T 细胞反应的特征
Ipi.+Nivo 组合期间的外周和肿瘤微环境。免疫疗法治疗以识别新的
EBV 特异性 T 细胞的表型特征与免疫治疗反应之间的关联。瞄准
3.,我们将研究与治疗引起的 NPC 特异性变化相关的 T 细胞克隆动力学
通过比较外周血和肿瘤活检样本中的 TCR 克隆多样性来评估免疫反应
不同阶段的治疗。总体而言,NPC 周围 EBV 特异性 T 细胞表型的表征
对肿瘤的多种前沿手段的运用不仅会提高我们对鼻咽癌的认识
免疫景观,但也有可能识别临床相关的 EBV 特异性 T 细胞表型
在未来的 NPC 免疫治疗试验中进行了测试。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Evan Newell其他文献
Evan Newell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Evan Newell', 18)}}的其他基金
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma
EBV特异性T细胞在EBV驱动的鼻咽癌检查点阻断免疫治疗中的作用
- 批准号:
10601371 - 财政年份:2021
- 资助金额:
$ 60.34万 - 项目类别:
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma
EBV特异性T细胞在EBV驱动的鼻咽癌检查点阻断免疫治疗中的作用
- 批准号:
10281126 - 财政年份:2021
- 资助金额:
$ 60.34万 - 项目类别:
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma
EBV特异性T细胞在EBV驱动的鼻咽癌检查点阻断免疫治疗中的作用
- 批准号:
10457484 - 财政年份:2021
- 资助金额:
$ 60.34万 - 项目类别:
相似海外基金
Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
- 批准号:
DP240100640 - 财政年份:2024
- 资助金额:
$ 60.34万 - 项目类别:
Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
- 批准号:
23K01889 - 财政年份:2023
- 资助金额:
$ 60.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10452217 - 财政年份:2022
- 资助金额:
$ 60.34万 - 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10670838 - 财政年份:2022
- 资助金额:
$ 60.34万 - 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
- 批准号:
DP200100492 - 财政年份:2020
- 资助金额:
$ 60.34万 - 项目类别:
Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
- 批准号:
407264 - 财政年份:2019
- 资助金额:
$ 60.34万 - 项目类别:
Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
- 批准号:
18K18240 - 财政年份:2018
- 资助金额:
$ 60.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
- 批准号:
17K12379 - 财政年份:2017
- 资助金额:
$ 60.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
- 批准号:
17K13937 - 财政年份:2017
- 资助金额:
$ 60.34万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
- 批准号:
8742767 - 财政年份:2014
- 资助金额:
$ 60.34万 - 项目类别: